论文部分内容阅读
应用人白细胞抗原－Ａ２阳性（ＨＬＡ－Ａ＋２）黑色素瘤病人的瘤块中分离得到的肿瘤浸润性淋巴细胞（ＴＩＬ），进行ＨＬＡ－Ａ２限制性ＴＩＬ抗人黑色素瘤细胞作用的研究。在实验中发现，ＴＩＬ对自身和同种异体的ＨＬＡ－Ａ＋２黑色素瘤细胞具有杀伤作用，而对ＨＬＡ－Ａ－２黑色素瘤细胞及ＨＬＡ－Ａ＋２非黑色素瘤细胞无作用。选择重组白细胞介素４（ｒＩＬ－４）＋肿瘤坏死因子α（ＴＮＦα）能促进黑色素瘤细胞ＨＬＡ－Ａ２表达量，并增强ＴＩＬ对瘤细胞的杀伤活性。抗ＣＤ３、抗ＨＬＡ－ＡＢＣ和抗ＨＬＡ－Ａ２单抗具有明显抑制ＴＩＬ的抗瘤细胞活性。结果表明ＴＩＬ杀伤黑色素瘤细胞依赖于Ｔ细胞受体（ＴＣＲ）对瘤细胞共同抗原的识别，并有主要组织相容性复合体－Ⅰ类分子参与。
Tumor-infiltrating lymphocytes (TIL) isolated from tumor masses of patients with human leukocyte antigen-A2 positive (HLA-A+2) melanoma were used to study the effect of HLA-A2-restricted TIL against human melanoma cells. In experiments, it was found that TIL has killing effect on self and allogeneic HLA-A+2 melanoma cells, but has no effect on HLA-A-2 melanoma cells and HLA-A+2 non-melanoma cells. Selecting recombinant interleukin 4 (rIL-4) + tumor necrosis factor alpha (TNFα) can promote the expression of HLA-A2 in melanoma cells and enhance the killing activity of TIL on tumor cells. The anti-CD3, anti-HLA-ABC and anti-HLA-A2 monoclonal antibodies had significant anti-tumor activity against TIL. The results showed that TIL killing melanoma cells depended on T cell receptor (TCR) recognition of tumor cell common antigens and involved major histocompatibility complex-I molecules.